Roche Holding AG (ROP.SW) — the peer cohort

As of 2026-11-13 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Roche Holding AG ranks 16 of 16 in its cohort on the Closelooknet composite (57/100) — the cohort is led by Halozyme Therapeutics Inc at 72/100.

Name	Composite	Momentum	Quality	Valuation	Signal	Off 52w high
ROP.SW Roche Holding AG	57	86	84	52	ok	0.7%
HALO Halozyme Therapeutics Inc	72	73	94	49	info	25.2%
ONC BeOne Medicines AG	65	89	64	29	ok	1.9%
REGN Regeneron Pharmaceuticals Inc	65	87	72	46	neutral	4.1%
ANN.AU Ansell Ltd	64	96	48	50	ok	1.9%
ARGX.BR Argen-X	64	79	75	25	ok	5%
LLY Eli Lilly and Company	64	92	90	22	neutral	2.2%
ROVI.MC Laboratorios Farmaceuticos ROVI	64	62	77	47	info	18.8%
SAN.PA Sanofi SA	64	75	70	64	bull	0.6%
UCB.BR UCB SA	64	75	71	42	info	1.6%
ARGX argenx NV ADR	63	71	74	25	ok	10.5%
DXCM DexCom Inc	63	73	79	36	bull	12.1%
ORNAV.HE Orion Oyj A	63	94	84	29	ok	0.8%
ORNBV.HE Orion Oyj B	63	93	84	29	ok	1%
HQY HealthEquity Inc	62	76	70	40	ok	6.2%
MEDP Medpace Holdings Inc	62	88	74	25	ok	5.8%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-13

Quick answers

Who are Roche Holding AG's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), BeOne Medicines AG (ONC), Regeneron Pharmaceuticals Inc (REGN), Ansell Ltd (ANN.AU), Argen-X (ARGX.BR), Eli Lilly and Company (LLY), Laboratorios Farmaceuticos ROVI (ROVI.MC), Sanofi SA (SAN.PA) and others, as of 2026-11-13.

How does ROP.SW score against its peers?

Roche Holding AG's composite reads 57/100, ranking 16 of 16 in its cohort as of 2026-11-13; the cohort's highest composite is Halozyme Therapeutics Inc at 72/100. Closelooknet scores are research diary readings, not ratings or advice.